You are here > Investor’s information

Resources helps performance!

Investor’s information

 

Promethera Biosciences has completed in October 2014 a third financial round (C-Round, first closing) of 20.3 million euros (~USD 31.4 million).

 

This round led by Vesalius Biocapital and Boehringer Ingelheim includes new investors as SFPI-FPMI and SMSInvestments.

 

Proceeds will be used to further develop the pre-clinical and clinical pipeline in the targeted liver indications.

 

 

The current investor's are:

 

Founders & Management   
  Pr Etienne Sokal
  Sopartec
  Management
Venture Capital Funds
  Vesalius Biocapital  (Lead investor)
  LRM
  Life Science Research Partners
  Vives Fund
  SRIW
  NivelInvest / Start-up SA

  Capital & Croissance/Financière Spin-off Luxembourgeoise

  Boehringer Ingelheim Venture Fund
  Shire
  Mitsui Global Investment
  ATMI
  ATMI LifeSciences
  SFPI-FPIM
  SMS Investment
Business Angels

 

Details on investors:

Vesalius Biocapital S.A.
SICAR is a venture capital fund focusing on the creation and growth of European non-quoted life science companies. The Fund invests in those areas that have highest profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery technologies as well as (non-) clinical diagnostics and screening tests with a high utility level.

 

SRIW
(Société Régionale d'Investissement de Wallonie) Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st Century.

 

Boehringer Ingelheim Venture Fund
The Boehringer Ingelheim Venture Fund was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. These may include – but are not limited to - novel technologies to address so far undrugable targets, new generation vaccines and new biological entities, such as antibody-dependent oncolysis. Novel therapeutic targets and disease-related biomarkers, as well as new approaches in regenerative medicine, are an additional focus.

 

Shire
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

 

Mitsui Global Investment 

Mitsui Global Investment (MGI) is a subsidiary of Mitsui & Co. Ltd. which invests in opportunities that have potential for growth. Headquartered in Tokyo, the company has offices in Silicon Valley, New York, Shanghai, Beijing, Mumbai and London (Alliance Team office) and its investments reach beyond these geographical barriers, reflecting a diversified global portfolio.

 

ATMI
ATMI LifeSciences is a leader in single-use technologies, products and systems for mixing, storage, bioreactors, cell culture technology, fluoropolymer-based products, and custom-engineered, flexible packaging solutions. The company’s cleanroom manufacturing experience, combined with its fundamental knowledge of bioproduction — especially within cell culture — help drive development of specific single-use technologies that are well-adapted to process operations. All products comply with internal, industry and regulatory standards and many of their products are completely animal derived components free (ADCF). All ATMI manufacturing facilities house ISO Class 5 cleanroom conditions, follow European current Good Manufacturing Practices (cGMP) and are ISO9001/2008 certified.

 

NivelInvest/Start-up SA
NivelInvest was created in march 1987 as a joint venture between public and private sectors to bring financial and human means dedicated to promotion, development management, strategic guidance, diversification and relocation of business in the Brabant Wallon Area in order to better valorize regional ressources and create stable and durable environment.

 

Capital & Croissance groupe investsud

Capital & Croissance groupe investsud is a group of specialized venture capital funds including Financière Spin-off Luxembourgeoise dedicated to encourage industrial and commercial implementation of results from research by Universities or other companies. The "Financière Spin-Off Luxembourgeoise" was created as a joint venture by the Walloon region and Investsud.

 

LRM
LRM is a profit driven investor. It offers entrepreneurs a unique combination of venture capital, project financing and real estate. LRM invests in the Life Sciences sector, focussing on promising players. LRM provides companies with the necessary instruments to develop faster and create added value for all stakeholders

 

Sopartec SA/Vives Fund  
Sopartec is the Technology Transfer Office and fully owned subsidiary of the Université catholique de Louvain (UCL). In close cooperation with the UCL Research Administration (ADRE - Administration de la Recherche), Sopartec is in charge of the management and commercialization of the UCL Intellectual Property for the benefit of society, the regional economy, the inventors and the University. Sopartec is also managing the Vives fund, a  €15 M seed investment fund dedicated to technology companies exploiting the R&D performed in UCL

 

 

SFPI-FPIM

 

The Federal Holding and Investment Company was created on 1 November 2006 as a result of a merger between the Federal Participation Company and the Federal Investment Company. The federal government is the sole shareholder of the Federal Holding and Investment Company. SFPI-FPIM centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy. The core business of SFPI-FPIM is, as an investment company, to invest in companies with an attractive added value for the society in one of the SFPI-FPIM priority sectors, and, as a holding company, to acquire equity in companies that are of strategic importance as far as federal policy is concerned, either making use of its own funds or by using funds that the state provides per project. www.sfpi-fpim.be 

 

SMSInvestments:

SMS Investments is a Luxemburg based subsidiary of the German SMS group, a family-owned group of companies active in plant and machinery construction for the processing of steel and NF metals. Via its internal asset management activities SMS group invests into a diversified portfolio consisting of liquid assets as well as of private equity and venture capital. 

Contacts

PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
(Belgium)
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea